Gastrointestinal Therapeutics Market Report 2026

Gastrointestinal Therapeutics Market Overview

• Gastrointestinal Therapeutics market size has reached to $42.3 billion in 2025 • Expected to grow to $55.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% • Growth Driver: The Rise In Inflammatory Bowel Diseases Drives The Growth Of The Market Due To Increasing Demand For Targeted Therapeutics • Market Trend: Innovative Capsule Therapy Enhances Treatment Outcomes And Patient Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Gastrointestinal Therapeutics Market?

Gastrointestinal therapeutics refers to the range of drugs, biologics, and treatment solutions used to prevent, manage, or cure disorders affecting the gastrointestinal tract, including the esophagus, stomach, intestines, liver, pancreas, and gallbladder. These therapies target conditions such as acid reflux, ulcers, irritable bowel syndrome, Crohn’s disease, and gastrointestinal cancers. The main product types of gastrointestinal therapeutics are over-the-counter gastrointestinal therapeutics and prescription-based gastrointestinal therapeutics. Over-the-counter gastrointestinal therapeutics refers to non-prescription medications used to relieve common digestive issues such as heartburn, indigestion, gas, constipation, and diarrhea. These therapeutics are administered through various routes of administration, including oral, intravenous, and others. They are used for several applications, such as inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The products are distributed through multiple distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by a range of end users such as hospitals, clinics, ambulatory surgical centers, diagnostic laboratories, and others.

What Is The Gastrointestinal Therapeutics Market Growth Forecast?

The gastrointestinal therapeutics market size is expected to see strong growth in the next few years. It will grow to $55.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to development of targeted biologics and immunotherapies, expansion of ambulatory surgical centers and diagnostic laboratories, rising adoption of oral and intravenous delivery systems, increasing online pharmacy penetration, innovation in probiotics and digestive enzyme formulations. Major trends in the forecast period include rising prevalence of gastrointestinal disorders, increased adoption of biologics and advanced therapies, expansion of over-the-counter therapeutics, growing focus on personalized gastrointestinal treatments, rising online and retail pharmacy distribution.

Global Gastrointestinal Therapeutics Market Segmentation

1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics 2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration 3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users Subsegments: 1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products 2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

What Is The Driver Of The Gastrointestinal Therapeutics Market?

The rising inflammatory bowel diseases is expected to propel the growth of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) is a chronic condition that causes inflammation of the digestive tract, primarily including Crohn's disease and ulcerative colitis. The rising inflammatory bowel diseases are due to genetic susceptibility, causing an abnormal immune response to gut microbes. Gastrointestinal therapeutics help manage and treat bowel diseases by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the rising inflammatory bowel diseases is driving the growth of the gastrointestinal therapeutics industry.

Key Players In The Global Gastrointestinal Therapeutics Market

Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

Global Gastrointestinal Therapeutics Market Trends and Insights

Major companies operating in the gastrointestinal therapeutics market are focusing on developing innovative therapies, such as sustained-release (SR) fixed-dose combination capsules, to improve patient compliance and enhance treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications that gradually release multiple active ingredients over time to maintain consistent drug levels and reduce dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, launched rabeprazole + levosulpiride SR capsules for treating gastrointestinal disorders in India. This formulation combines rabeprazole, a proton pump inhibitor that decreases stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, they offer effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is widely prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

What Are Latest Mergers And Acquisitions In The Gastrointestinal Therapeutics Market?

In April 2023, Merck and Co., Inc., a US-based pharmaceutical company, acquired Prometheus Biosciences, Inc., for $10.8 billion. With this acquisition, Merck and Co., Inc., aims to strengthen its immunology pipeline by advancing precision-based therapies for inflammatory diseases such as ulcerative colitis and Crohn’s disease. Prometheus Biosciences, Inc. is a US-based biotechnology company that specializes in precision therapeutics for immune-mediated diseases, particularly gastrointestinal disorders.

Regional Insights

North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gastrointestinal Therapeutics Market?

The gastrointestinal therapeutics market consists of sales of acid suppressants, antiemetic agents, antispasmodics, digestive enzymes, and prebiotics and probiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gastrointestinal Therapeutics Market Report 2026?

The gastrointestinal therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.